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ABSTRACT 
SYNTHESIS AND CHARACTERIZATION OF CLICKABLE DENDRIMER HYDROGELS 
FOR OCULAR DRUG DELIVERY 
By Jingfei Tian 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
in Biomedical Engineering at Virginia Commonwealth University 
Virginia Commonwealth University, 2014  
Director: Dr. Hu Yang, Associate Professor, Biomedical Engineering 
Topical medication is a standard treatment for glaucoma. However, frequent dosing makes the 
therapy inconvenient and patient unfriendly. There is a great need to develop new topical 
formulations that provide long lasting noninvasive drug release. In this thesis, novel clickable 
dendrimer hydrogels for anti-glaucoma drug delivery were synthesized and characterized. 
Polyamidoamine (PAMAM) dendrimers have been widely applied for drug delivery. The 
physical characteristics they possess include monodispersity, water solubility, encapsulation 
ability, and a large number of surface groups. Polycationic PAMAM dendrimer G3 was surface 
modified with alkyne-PEG5-acid and then reacted with polyethylene glycol bisazide (PEG-BA, 
1100 gmol
-1
) through click chemistry to form a cross-linked hydrogel. The resulting hydrogels 
were characterized in terms of mechanical properties, swelling, structural morphology, pH-
dependent degradation, anti-glaucoma drugs (brimonidine tartrate and timolol maleate) release 
and cytotoxicity. To fully explore PAMAM dendrimers to make clickable hydrogels, polyanionic 
PAMAM dendrimer G4.5 was also surface modified with propargylamine to possess alkyne 
groups and successfully formed a hydrogel with PEG-BA. The work conducted in the thesis 
 xi 
shows that clickable dendrimer hydrogels were successfully developed and shown to possess 
desired properties for delivery of anti-glaucoma drugs. 
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CHARPTER 1 INTRODUCTION AND BACKGROUND 
1.1 Glaucoma 
Glaucoma is an intraocular pressure (IOP)-associated ocular neuropathy characterized by 
abnormal structural and functional features at the optic nerve head, neuroretinal rim, optic cup, 
retinal ganglion cell axons, lamina cribrosa and loss of visual field
1
. Glaucoma can cause 
devastating and irreversible damage to optic nerves. 
Glaucoma has been recognized as a primary cause of blindness globally 
2, 3
. As reported in the 
blindness prevalence survey
2
, it contributes to 12% of worldwide blindness. Glaucoma accounts 
for 4% permanent blindness in more than 2 million glaucomatous patients in the United States
4, 5
. 
In China, there are approximately 9.4 million of glaucoma patients at the age of 40 or older 
6
. 
Population-based surveys
7, 8 
show that, glaucoma, especially primary open-angle glaucoma, has 
destructive impacts. It is considered to be a top factor contributing to irreversible vision loss 
among black people in Africa
 9-11 
and African Americans
12
. 
Glaucoma can be classified into two major types: primary glaucoma and secondary glaucoma. 
Primary glaucoma is diagnosed as the group of glaucomatous disorder without preexisting 
systemic or ocular diseases. Secondary glaucoma, in the contrary, refers to glaucomatous 
exfoliation 
13
, iridocorneal endothelial syndrome (ICE) syndrome
14
 , disorder that is associated 
with ocular or systemic comorbidity such as eye injury, eye tumors, systemic disease like 
diabetes
15
 , and so on. 
Based on anatomical features at trabecular meshwork, the drainage pathway of aqueous humor 
16
, 
glaucoma can also be grouped into open-angle glaucoma and closed-angle glaucoma. Open-
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angle glaucoma has normal iridocorneal angle appearance, while the iridocorneal angle of 
closed-angle glaucoma is physically blocked by periphery tissue. 
Elevated IOP has long been the research focus of the etiology of glaucoma. A survey shows that 
the IOP of 48% to 80% of patients are above the normal value, usually estimated at 21 mm Hg
16
. 
Even though glaucomatous vision loss is not necessarily associated with IOP, the risks of 
glaucoma development rise with a high level of IOP
17
. Primary open angle glaucoma accounts 
for 90% of the disease. However, its pathophysiology remains unclear. Closed-angle glaucoma 
occurs when aqueous humor cannot flow through the pupil into the anterior chamber (pupillary 
block). This situation causes pressure increase behind the iris and deforms the iris anteriorly (iris 
bombe), and thus mechanically blocks the drainage pathway and prevents aqueous humor 
outflow through the trabecular network
16
 . 
A number of risk factors have been recognized for open-angle and closed-angle glaucoma 
including advancing age, family history 
18
, history of ocular trauma 
19
, hypertension and 
diabetes
15
, eye injury, eye tumors, ICE syndrome 
14
, vasospastic diseases, and a reduction in 
blood circulation to the optic nerve. Besides, there exist ethnic-dependent variations in the 
prevalence of glaucoma. In particular, the prevalence of open-angle glaucoma appears to be 
threefold more in African Americans than in Caucasians in the United States
12, 20
.  Furthermore, 
primary open-angle glaucoma is the major cause of blindness among African-Americans
12
. In 
contrast, Asians are more likely to develop closed-angle glaucoma
21
. 
1.2 Glaucoma management 
As of today, lowering elevated IOP to normal range remains a primary treatment strategy 
worldwide. To prevent vision loss, eye surgeries (like laser trabeculoplasty, iridotomy, 
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iridectomy, canaloplasty and trabeculectomy) can be performed to enhance aqueous humor 
drainage. However, success of surgeries depends on surgical skills and eye responses of patients. 
In addition, glaucomatous surgery may lead to fibrosis formation, which is a risk factor for 
cataract. To overcome disadvantages and limitations of surgery, medication is widely adopted for 
glaucoma management. 
1.2.1 Drug delivery 
Anti-glaucoma agents in common clinical use include prostaglandin analogs, 
parasympathomimetic (miotic) agents, including cholinergic and anticholinesterase agents, 
carbonic anhydrase inhibitors, adrenergic antagonists, alpha2 agonists, hyperosmotic agents and 
so on 
22-25
. According to chemical structure and pharmacologic effects, medications are divided 
into different groups (Table 1-1). 
Usually, the combination of anti-glaucoma drugs from different groups may have better 
treatment outcomes. For instance, adrenergic agent brimonidine tartrate and beta blocker timolol 
maleate are often combined to make a better control over IOP. To this end, brimonidine tartrate 
and timolol maleate are used as model drugs in this thesis. 
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Table 1-1 Summary of mechanism and adverse effect of different types of anti-glaucoma drugs (adapted from26). 
Category Name Mechanism of action Adverse effects 
Prostaglandin 
analogs 
Latanoprost (Xalatan) Increased USO (uveoscleral 
outflow ) 
Pigmentation of eyelashes, eyelid skin 
pigmentation, hyperemia (red eye), flu-like 
symptoms (joint/muscle pain and 
headache) 
 Bimatoprost (Lumigan) Increased USO (uveoscleral 
outflow ) 
Blurred vision, eyelid redness, eye 
discomfort, permanently darken iris, 
darken/thicken eyelashes 
 Travoprost (Travatan) Increased USO (uveoscleral 
outflow ) 
Blurred vision, eyelid redness, eye 
discomfort, permanently darken iris, 
darken/thicken eyelashes 
Beta blockers Timolol Decrease aqueous production by 
ciliary body 
Bronchospasm, bradycardia, depression, 
impotence 
 Betaxolol Decrease aqueous production by 
ciliary body 
Fewer pulmonary complications due to 
selective Beta blockage 
 Levobunolol (Betagan) Decrease aqueous production  
Adrenergic 
agents 
Brimonidine Decrease aqueous production, 
increase USO 
Blurring, foreign body sensation, eyelid 
edema, dryness, headache, fatigue, 
hypotension, depression, insomnia 
 Aproclonidine Decrease aqueous production, 
increase USO 
 
Miotics Pilocarpine Increase trabecular outflow by 
contraction of the ciliary muscle, 
opening the trabecular meshwork 
Posterior synechia, keratitis,   miosis, brow 
ache, cataract, myopia, retinal tear, 
dermatitis, increased salivation 
Carbonic 
anhydrase 
inhibitors 
Dorzolamide Decrease aqueous production by 
inhibiting carbonic anhydrase in 
the ciliary body 
Eye irritation, bitter taste 
 Brinzolamide Decrease aqueous production by 
inhibiting carbonic anhydrase in 
the ciliary body 
Eye irritation, bitter taste 
  Acetazolamide Decrease aqueous production by 
inhibiting carbonic anhydrase in 
the ciliary body 
Malaise, depression, weight loss, kidney 
stones 
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Ocular drug delivery is challenging and complicated due to the presence of various anatomical 
and physiological barriers. Depending upon administration routes such as topical administration, 
systemic administration and injection, delivery drugs may encounter different barriers. Table 1-2 
summarizes these specific drug delivery barriers facing various administration routes. 
Table 1-2 Administration routes and anatomical and physiological barriers of ocular drug delivery (adapted from27) 
Administration route  Anatomical and physiological barriers 
Topical administration  Cornea, sclera and conjunctiva 
Systemic administration  Blood-aqueous barrier and blood-retina barrier, targeted ocular 
tissue 
Injectable administration Periocular 
administration 
Dynamic including conjunctival blood and lymphatic circulation 
static, and metabolic barriers 
Intravitreal 
administration 
Non-uniform drug distribution in vitreous, vitreous is barrier for 
retinal gene delivery 
 Hydrogel  1.2.1.1
Hydrogels are three-dimensional crosslinked polymer networks that can absorb substantial 
amounts of aqueous solutions.  Due to their high water content, hydrogels bear resemblance to 
natural tissue more than other types of synthetic biomaterial. And this unique property of 
hydrogel has sparked particular interests in drug delivery application. A variety of polymers such 
as PLA, PLGA
28
, chitosan
29
and dendrimer
30
 can be utilized to synthesize hydrogels. Among 
them, PAMAM dendrimers have been widely applied for drug delivery due to their beneficial 
physical characteristics include monodispersity, water solubility, encapsulation ability, and a 
large number of functional groups on the surface. Thus, using dendrimers as building blocks to 
make hydrogels can integrate the unique characteristics and structural features into the hydrogel 
network. 
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Hydrogels can be made by using a variety of methods. In general, they are divided into non-
covalently crosslinked methods and covalently crosslinked methods. As a branch of covalent 
chemical reaction, click chemistry, first described by K. Barry Sharpless and Valery Fokin in 
2001 
31, 32
 , has been applied to many research fields including biomaterial and drug delivery
33, 34
. 
As a highly efficient chemistry method, it has also been applied to hydrogel synthesis. 
 Contact lens 1.2.1.2
Drug-eluting contact lens can be generated by various methods including soaking of lenses in 
drug solution, copolymerization of the contact lens hydrogels with functional monomers (which 
provide binding points for drugs and communicate functionality to the contact lens), dispersion 
or immobilization on the contact lens surface of drug-loaded colloidal nanoparticles, molecular 
imprinting and supercritical solvent impregnation method
35
. 
After a drug-eluting contact lens is placed on the eye, a normal human tear film, about 7-10 μm 
in thickness, partitions into two parts:  pre-lens tear film and post-lens tear film
36
. The drug-
eluting contact lens then releases drug into the pre-lens tear film and the post-lens tear film. The 
drugs released into the pre-lens tear film are likely to be absorbed into the conjunctiva or drained 
through the canaliculi. They eventually enter the systemic circulation. However, drugs released 
into the post-lens tear film will either be transmitted through the cornea or be diffused radially 
out into the outer tear lake. Resulting from the very large discrepancy of the post-lens tear film in 
the thickness (~ 5 μm) and contact area with a radius of 5 mm, almost the entire drug amount 
released into the post-lens tear film diffuses into the cornea
37
.  
Scientists have tried to apply contact lens to glaucoma treatment
37-39
 . Nevertheless, a majority of 
the current relative researches are only performed to evaluate therapeutic contact lens in vitro. In 
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vivo evaluation of contact lens in ocular drug delivery has not been widely and deeply performed 
and deserves further investigation. 
 Liposome 1.2.1.3
First studied in 1981, Smolin and coworkers 
40
applied liposomes in ocular drug delivery. Since 
then, scientists have being tried to fulfill the potential of liposomes in ocular drug delivery in 
various approaches
41
 and have had great progresses. 
A liposome composed of a lipid bilayer is an artificially-prepared vesicle. It encapsulates an 
aqueous region inside a hydrophobic membrane. Due to this biphasic nature, both lipophilic and 
hydrophilic drugs can be encapsulated in the liposome. If the drug is water soluble, it will be 
entrapped in the aqueous region. If the drug is hydrophobic, it will associate with the 
hydrophobic membrane or dissolve in the lipid bilayer
42
. In drug delivery process, drugs or gene 
therapy can be delivered into the cell after the lipid bilayer fusing with the cell membrane. In the 
case of topically applied liposomes, viscosity inducing agents is indispensable in the way of 
providing a consistency which is easy to apply and has better patient acceptability
43
. However, 
despite of many advantages including nano-scaled size, better biocompatibility, biodegradability, 
stability, sustained drug release and toxicity reduction, its disadvantages existing in aspects of 
low loading and manufacturing difficulties
44
 obstruct its way to be made into marketed products. 
1.2.2 Eye drop 
Eye drop is the most common and conventional form of topical medication for glaucoma 
treatment.  However, the effectiveness of eye drop is compromised by several drawbacks such as 
low drug penetration, low bioavailability, poor patient compliance, frequent dosing requirement 
etc. Typically less than 5% of drugs in eye drops can be successfully delivered to the ocular 
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tissues of the anterior chamber and almost negligible quantities to the posterior chamber
45, 46
. To 
overcome those deficiencies, new and effective drug delivery formulations such as drug-eluting 
contact lens, liposome-based drug delivery vehicles, hydrogels, nanocarriers and implant devices 
are under development. 
1.2.3 Gene therapy 
Gene therapy is a neuroprotective approach aiming at optic nerve regeneration and regaining of 
vision. Given that the slow death of retinal ganglion cells (RGCs) and their axons account for 
progressive vision loss and permanent blindness
47
, gene therapy primarily focuses on 
regeneration of RGCs. There are several theories that support this approach. Mechanical theory 
postulates that decreased neurotrophic factor (NF) production in retinal ganglion cells due to 
elevated IOP triggers retinal ganglion cells apoptosis. In the meanwhile, increased IOP obstructs 
the bidirectional axonal flow of NF and proteins made by RGCs
48
 between RGCs, leading to 
axonal damage
49
. The vascular theory, however, associates deterioration of RGCs with 
abnormally low ocular blood flow, which is postulated to play a major role in the production of 
free radicals and consequent oxidative stress on RGCs
 50, 51
.  
It was found that NF, especially brain-derived neurotrophic factor (BDNF)
52
, ciliary 
neurotrophic factor (CNTF) 
53,54
 and glial cell line-derived neurotrophic factor (GDNF)
55 
increase the survival of RGCs.  
In general, gene delivery system can be divided into two types based on types of carriers. Viral 
gene delivery utilizes genetically modified viruses to deliver therapeutic gene. Nonviral gene 
delivery typically employs synthetic carriers like polymeric and lipidic macromolecules to 
deliver genetic therapeutics
56
. In addition to RGC, other specific tissues contribute to glaucoma 
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formation including the trabecular meshwork, ciliary body and ciliary epithelium. A recent study 
showed the success of gene expression mediated with intracameral injection of a lentiviral vector 
for as long as 15 months in the trabecular meshwork, iris and ciliary body of nonhuman 
primates
57
.  
1.3 Click Chemistry 
Click chemistry is a group of chemical reactions which meet many criteria. The desirable click 
chemistry reaction should be modular, stereospecific, wide in scope, give very high yields, and 
generate only inoffensive byproducts
31
. The process would preferably have simple reaction 
conditions, use readily available starting materials and reagents and use no solvent or use a 
solvent that is benign or easily removed (preferably water), provide simple product isolation by 
non-chromatographic methods. It is unlikely to find such a reaction that perfectly fits the criteria. 
However, several reactions have been proved to fit the criteria better than the others. Among 
them, discovered by Rolf Huisgen, the Huisgen 1, 3-dipolar cycloaddition
58
 (Figure 1-1) is the 
most popular one and has recently gained a considerable amount of attention. 
 
 
Figure 1-1. Schematic of azide-alkyne Huisgen cycloaddition. Catalyzed by Cu (I), azide and alkyne react to give a 
1, 2, 3-triazole. 
In solution, alkyne groups and azide groups are quietly inert. However, they can react with each 
other and form a triazole immediately as the catalyzer added. Cu (I) is gained by reducing Cu (II) 
oxidation state to Cu (I) by adding a reducing agent. The advantage of this method over directly 
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adding Cu (I) compound is that the presence of reducing agent makes up for any oxygen which 
may have gotten into the system. Oxygen oxidizes the Cu (I) to Cu (II) which impedes the 
reaction and results in low yield. The most commonly used Cu compound is copper sulfate. And 
sodium ascorbate is the most commonly used reducing agent.  
1.4 Dendrimer 
Dendrimers are a group of highly branched, symmetric spherical macromolecules. Due to a 
number of unique features: nanoscale size, monodispersity, manipulable surface modification, 
water-solubility and multivalency, they has been widely applied to drug delivery research. 
PAMAM dendrimers, composed of an ethylenediamine (EDA) or an ammonia core with methyl 
acrylate and ethylene diamine branches, have been the most investigated in dendrimer family for 
drug delivery. The properties of PAMAM dendrimer are dominated by surface functionality. Full 
generations (cationic) have amine surface groups and half generations (anionic) have carboxyl 
surface groups.  To deliver drugs, drugs can be physically encapsulated in dendrimers or 
chemically conjugated to dendrimers. 
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CHARPTER 2  MATERIAL AND METHOD 
2.1 Material and reagent 
Table 2-1 List of materials and reagents and abbreviations 
Material Abbreviation 
4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride DMTMM 
Alkyne-PEG5-acid  
Brimonidine tartrate BT 
Cell proliferation reagent WST-1 assay  
Copper(II) sulfate pentahydrate CuSO4·5H2O 
Dialysis tubing (MWCO 3500)  
Dimethylformamide DMF 
Ethylenediaminetetraacetic acid EDTA 
Generation 3 polyamidoamine dendrimer with core of ethylenediamine (EDA) G3 
Generation 4.5 polyamidoamine dendrimer with core of ethylenediamine (EDA) G4.5 
Human corneal epithelial cells HCECs 
Human IL-1α ELISA kit  
Hydrochloric acid HCl 
Phosphate buffer solution (of pH 4.5, 5.5 and 7.4) PBS 
Poly(ethylene glycol) bisazide (MW=1100 gmol-1) PEG-BA 
Propargylamine,  
Sodium ascorbate  
Sodium Bicarbonate NaHCO3 
Timolol maleate TM 
Azide-PEG5-acid   
 12 
 
2.2 Equipment 
Table 2-2 List of equipments 
List of equipment Function 
3500 MW Dialysis Tubing 
For hydrogel purification and weight specific elution of 
drug into filtrate 
Flexi-Dry FTS System Freeze dry system to dry frozen samples 
Hot Water Bath 
To provide 37˚C aqueous environment to simulate drug 
release in physiological conditions in vitro 
Incubator Temperature and humidity control of cell culture 
MTS Bionix 200 ® Mechanical Testing System Measure mechanical properties of materials 
Rotary Evaporator, Heidolph LABOROTA 4000 
Distillation of low boiling point chemicals from mixture of 
compounds 
Ultra Violet Visible (UV-Vis) Spectrophotometer 
Quantitative tool using light absorption to measure the 
amount of sample released 
Varian Mercury-300 MHz Nuclear Magnetic 
Resonance (NMR) spectrometer 
Measuring chemical shifts of protons, 1H-NMR 
Weighing Balance Used to measure mass of materials needed 
Scanning Electron Microscope (JEOL LV-5610) 
Obtain high resolution images of hydrogels for morphology 
characterization 
Zeiss Invertoskop 40C Microscope Examining cell growth and for cell counting 
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2.3 Experimental methods 
2.3.1 Synthesis of clickable cationic PAMAM dendrimer hydrogel 
 Synthesis of PAMAM G3-alkyne conjugates 2.3.1.1
To a solution of 40mg of dendrimer G3 in 1mL of 0.1M NaHCO3, 84.6mg of DMTMM was 
added. The solution of 84.6 mg of alkyne-PEG5-acid in 500µL of DI water was added dropwise. 
The molar feed ratio of amine: alkyne: DMTMM is 1:1.5:1.65.  The reaction mixture was stirred 
overnight at room temperature. Product was purified by dialyzing against DI water and then 
freeze-dried to obtain G3-alkyne conjugates. G3-alkyne conjugates were characterized using 
Varian Mercury-300 MHz NMR. 
 
Figure 2-1 Synthesis of G3-alkkyne conjugates. 
 G3 hydrogel synthesis and anti-glaucoma drug encapsulation 2.3.1.2
53.9 mg of PEG-BA was dissolved in 533 µl DI water, and then mixed with 40.0mg of G3-
alkyne. The mixture was vigorously stirred and then evenly divided to 3 vials: control group, BT 
group and TM group. Drug-loaded hydrogels were prepared by adding 4.0 mg of brimonidine 
tartrate to BT group and 4.0 mg of timolol maleate to TM group. 2.7 mg of CuSO4·5H2O was 
added to resolve in each group. The vials were vigorously stirred for 30 seconds and hydrogels 
formed instantly upon addition of 3.8 mg ascorbic acid to each group. The molar ration of alkyne: 
azide: Cu: sodium ascorbate was 1:1.5:0.5:1. 
 14 
 
 
 
 
 
 
 
 
Figure 2-2 Synthesis of clickable cationic PAMAM dendrimer hydrogel on the basis of G3-alkyne and PEG-BA.  
2.3.2 Synthesis of clickable anionic PAMAM dendrimer hydrogel 
 Synthesis of PAMAM G4.5-alkyne conjugates 2.3.2.1
To a solution of 50.0 mg PAMAM dendrimer G4.5 in 3.5 mL of 0.1M NaHCO3, 84.0 mg of 
DMTMM was added. The solution of 15 µL of propargylamine in 500 µl DMF was added 
dropwise. The reaction mixture was stirred overnight. Upon removal the solvents under reduced 
pressure, the remaining residue was dialyzed against DI water and freeze-dried to obtain G4.5-
alkyne conjugates. G4.5-alkyne conjugates were characterized using Varian Mercury-300 MHz 
NMR. 
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Figure 2-3 Synthesis of G4.5-alkyne conjugates. 
 Determination of alkyne in G4.5 2.3.2.2
8.0 mg of G4.5-alkyne conjugate was dissolved in 1.4 mL DI water, and then mixed with 12.1 
mg of azide-PEG5-acide. The mixture was vigorously stirred. 4.5mg of CuSO4·5H2O was added 
to resolve in the solution. The solution of 7.2 mg of sodium ascorbate in 100 µL of DI water was 
added to the stirring system dropwise. The molar ration of G4.5-alkyne conjugate: azide: Cu: 
sodium ascorbate was 1:128:64:128. 
 
Figure 2-4 Schematic Representation of the reaction between G4.5-alkyne and N3-PEG5-CH2CH2COOH. 
 
 
Sodium ascorbate 
 CuSO4 
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 G4.5 hydrogel synthesis                      2.3.2.3
17.2 mg of PEG-BA was dissolved in 200 µl of DI water, and then mixed with 50.0 mg of G4.5-
alkyne. The mixture was vigorously stirred. Clickable hydrogel formed immediately upon 
sequential addition of 2.6 mg of CuSO4·5H2O and 3.7 mg of sodium. The molar ratio of alkyne: 
azide: Cu: sodium ascorbate was 1:1.5:0.5:1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5 Synthesis of clickable anionic PAMAM dendrimer hydrogel. 
2.3.3  Hydrogel purification 
Hydrogels were put into dialysis tube (MWCO 3500), then purified by dialysis against 1mM 
Ethylenediaminetetraacetic acid (EDTA) for 2 days. Dialysis against DI water for two days was 
further done to remove EDTA. 
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2.3.4 Characterization 
  1H NMR spectroscopy 2.3.4.1
 
1
H NMR spectra of were collected on a 300 MHz NMR spectrometer (Mercury-300). The 
solvent used was deuterium water (D2O), which has a chemical shift of 4.79 ppm.  
 Mechanical property study 2.3.4.2
The mechanical properties of G3 hydrogels were tested in terms of compressional property by 
using MTS Bionix 200 ® Mechanical Testing System and TestWorks 4.0 software. The three 
air-dried G3 hydrogels were 1.15mm, 1.09mm and 1.11mm at its width, and 1.47mm, 1.41mm 
and 1.58mm at its thickness respectively. Mechanical properties of the three scaffolds including 
peak load, peak stress and modulus were obtained. 
 Swelling degree measurement 2.3.4.3
Three air dried hydrogel samples were immersed into DI water at room temperature. At pre-
determined time intervals, samples were taken out, blot dried and weighed. The experiment 
stopped when the sample reached a stable weight. The swelling degree was calculated using the 
following equation: 
                    
     
  
 ×100, 
where wS is the weight of the swelling hydrogel and wd is the weight of dry hydrogel.  
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 PH-dependent hydrogel degradation study 2.3.4.4
The in vitro degradation of hydrogels was evaluated in 37 ˚C phosphate buffered saline (PBS) of 
three different pHs (pH4.5, 5.5 and 7.4). After air-dried and weighed, samples were individually 
immersed in a centrifugal vial with 1.2 ml of one of the three solutions and incubated at 37˚C in 
a thermostatic water tank. The sample residues were taken out, air-dried and weighed every 24 
hours for five days. The stability degree was calculated using the following equation: 
  Stability degree (%) = 
  
  
 ×100, 
where Wo is the weight of initial air-dried sample and Wd is the weight of the air-dried sample 
after incubation in PBS. These experiments were done for at least three samples of the same 
hydrogel. 
 Scanning electron microscopy (SEM) 2.3.4.5
SEM image were taken using a scanning electron microscope (JEOL LV-5610). Freeze-dried 
hydrogel sample was put on the stub over a double-sided sticky carbon sheet, and then sputtered 
for 60 seconds using Denton Vacuum Desk V TSC in vacuum. Then the platinum plated stub 
was placed inside the scanning electron microscope (JEOL LV-5610) chamber under high 
vacuum for image taking. 
 In vitro drug release studies 2.3.4.6
The drug-loaded hydrogels were immersed into 15ml of PBS (pH 4.5, pH 5.5 or pH 7.4) at 37˚C. 
At predetermined time intervals, 1 ml of release medium was withdrawn and estimated by 
Ultraviolet-visible (UV-vis) spectroscopy at 248 nm for brimonidine tartrate (BT)-loaded sample. 
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1 mL of fresh PBS, pre-equilibrated at 37˚C was immediately added to maintain its volume. The 
absorbance of the withdrawn solution was measured at each time-point and referenced against 
the standard curve: absorbance=00630*(concentration in microliter/ml) + 0.0050
59
 to indicate the 
cumulative amount (mg) of drug release shown by the following equation: 
                                 
           ∑                 
  
      
For timolol maleate, the upmost absorbance wavelength is 294nm, and its reference regression 
equation is absorbance=0.0186x+0.0032
60
. These experiments were done for at least three 
samples of the same hydrogel. 
 Cell culture 2.3.4.7
Human corneal epithelial cells (HCECs), purchased from Life Technologies Corporation, are 
normal human corneal epithelial cells isolated from dissected limbal sections, the progenitor-rich 
region where the sclera and cornea join. HCEC cells were cultured in Keratinocyte SFM at 37˚C 
in a humidified atmosphere containing 5% CO2 for 5 or 7 days or until 80%-90% confluent.  
 WST-1 assay 2.3.4.8
Cytotoxicity of G3 hydrogel was evaluated. 1mg of G3 hydrogel was immersed into 1ml of cell 
culture medium for 24 hours to gain degradation solution. HCECs were seeded in a 96-well cell 
culture plate at a density of 5x10
3
 cells per well. After 48 hours of culture in Keratinocyte SFM 
at 37˚C in a humidified atmosphere containing 5% CO2, cell culture medium was extracted and 
hydrogel degradation solution was added to sample groups. Untreated HECEs were used as 
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control group. The cell viability was assessed with WST-1. These experiments were done for at 
least three samples of the same hydrogel. 
 ELISA 2.3.4.9
G3 hydrogel was placed in cell culture medium for HCECs for 24 hours to gain hydrogel 
degradation solution.  200 µL of hydrogel degradation solution was added to treat HCECs as 
sample groups. After 48-hour incubation in Keratinocyte SFM at 37˚C in a humidified 
atmosphere containing 5% CO2, cell culture medium was collected and used for ELISA using 
Human IL-1α ELISA kit by Thermo Scientific. These experiments were done for at least three 
samples of the same hydrogel. 
 Statistical analysis 2.3.4.10
Statistical analysis was performed with Prism software. Most of the statistical analysis was based 
on one way analysis of variance (ANOVA: Single Factor) and Tukey's multiple comparison test. 
T-test was employed when appropriate. A p-value less than 0.05 was considered statistically 
significant for rejecting the null hypothesis. Recording data was done in Microsoft Excel 2012. 
Analysis of data and its graphical representation were done on Prism software, where the error 
bars represent standard deviations. 
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CHARPTER 3 RESULTS AND DISCUSSION 
3.1 Characterization of G3-alkyne conjugates 
Alkyne-PEG5-acid was conjugated to G3 in the presence of DMTMM. The amine group was 
highly reactive towards activated carboxyl. Activated carboxyl and amine groups formed an 
amide linkage between alkyne-PEG5-acid and G3. The conjugation of alkyne-PEG5-acid and G3 
was confirmed by 
1
H-NMR. In the 
1
H-NMR spectrum of G3-alkyne conjugate (Figure 3-1), the 
PEG proton peak (δ 3.71 ppm), multiple proton peaks of G3 (δ 2.35-3.40 ppm). Corresponding 
peak area was integrated to determine the average number of alkyne per G3-alkyne conjugate has. 
The results indicated that 66.3% surface groups of G3 dendrimer had been modified with alkyne 
groups. The molecular weight of G3-alkyne conjugate was calculated to be 13007gmol
-1
. 
 
 
Figure 3-1 
1H NMR (300 MHz) spectrum of G3-alkyne conjugates in D2O. 
 
 
 
G3 PAMAM dendrimer 
 
PEG 
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3.2 Characterization of G4.5-alkyne conjugates 
Propargylamine was conjugated to G4.5 in the presence of DMTMM to form an amide linkage 
between propargylamine and G4.5. The conjugation was confirmed by 
1
H-NMR after a further 
reaction with azide-PEG5-acid. The resultant compound was analyzed by using 
1
H-NMR (Figure 
3-2). The PEG proton peak (δ 3.71 ppm), multiple proton peaks of G4.5 (δ 2.35-3.40 ppm) and 
single proton peak of the single proton on the triazole (δ 6.14 ppm) indicated the success of the 
synthesis of G4.5-alkyne conjugates. Corresponding peak area was integrated to determine the 
average number of alkyne per G4.5-alkyne conjugate has. The results indicated that 7.7% surface 
groups of G4.5 dendrimer had been modified with alkyne groups. The molecular weight of G4.5-
alkyne conjugate was calculated to be 23663gmol
-1
. 
      
 
Figure 3-2 
1H NMR (300 MHz) spectrum of G4.5-alkyne conjugates in D2O. 
 
3.3 Formation of G3 and G4.5 hydrogels and anti-glaucoma drugs encapsulation 
G4.5 PAMAM dendrimer PEG 
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Procedures of G3 hydrogel formation and drug encapsulation are shown in Figure 3-3. G4.5 
hydrogel formation is shown in Figure 3-4. Hydrogel without drug loading was formed in vial 1. 
Hydrogel loaded with timolol maleate was formed in vial 2. Hydrogel loaded with brimonidine 
tartrate was formed in vial 3.  
  
 
 
Figure 3-3 G3 hydrogel formation and drug encapsulation. A: transparent solution of PEG-BA and G3-alkyne 
in 200 µl DI water. B: 4mg of timolol maleate added to vial 2 and 4mg of brimonidine tartrate added to vial 3.  
C: reaction solutions turned blue after CuSO4·5H2O was added. D: hydrogel formed immediately after sodium 
ascorbate added and stirred. The molar ratio of alkyne: azide: Cu: sodium ascorbate was 1: 1.5: 0.5: 1. 
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Figure 3-4 G4.5 hydrogel formation. A: transparent solution of PEG-BA and G4.5-alkyne in 200 µl DI water. B: 
Reaction solutions turned blue after CuSO4·5H2O added. D: Hydrogel formed immediately after sodium ascorbate 
added and stirred. The molar of alkyne: azide: Cu: sodium ascorbate was 1: 1.5: 0.5: 1. 
3.4 G3 hydrogel mechanical property 
The mechanical properties of G3 hydrogel were tested using the MTS Bionix 200 ® Mechanical 
Testing System in conjunction with TestWorks 4.0 software. The scaffolds mechanical 
properties of three air-dried G3 hydrogel samples including peak load, peak stress and modulus 
were obtained (Table 3-1).  
 Table 3-1 Mechanical property of G3 air-dried hydrogel  
Specimen # Width 
(mm) 
Thickness 
(mm) 
Peak Load 
(N) 
Peak Stress 
(MPa) 
Modulus 
(MPa) 
1 1.15 1.47 0.412 0.2 8.032 
2 1.09 1.41 0.457 0.3 7.797 
3 1.11 1.58 0.771 0.4 10.359 
Mean 0.12 1.49 0.547 0.3 8.729 
SD 0.03 0.09 0.196 0.1 1.416 
3.5 G3 hydrogel swelling property  
A B C 
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The swelling property of the hydrogels was examined. As shown in Figure 3-5 and Figure 3-6, 
swelling degree quickly increased at an average speed of 4.343% per minute in the first 70 
minutes. Afterwards until 580 minutes, swelling degree increased slows down with an average 
speed of 0.0765% per minute. At 1640 minute, G3 hydrogel displayed the maximal swelling 
degree of 349%.   
 
Figure 3-5 G3 hydrogel swelling property tested in DI water for about 1800 minutes at room temperature. 
 
Figure 3-6 G3 hydrogel swelling property tested DI water in the first 600 minutes at room temperature. 
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3.6 G3 hydrogel pH-dependent degradation study 
In vitro degradation studies were conducted to evaluate the hydrogel’s stability in PBS of three 
different pHs (4.5 5.5 7.4) at 37˚C. As samples immersed in PBS, they began to swell 
immediately. Figure 3-7 shows that no degradation was shown after samples immersed in pH 7.4 
PBS for all 5 days. As for samples immersed in pH 4.5 and pH 5.5 PBS, the degradation rate was 
rather slow. The hydrogel immersed in pH 4.5 PBS showed no degradation in the first 3 days at 
all. On the fourth day, it lost 3.0% of its initial weight and showed no further degradation on the 
fifth day. As for the hydrogel tested in the pH 5.5 PBS, it showed no degradation in the first 4 
days, and on the fifth day, it lost 2.6% of its initial weight.  No significant statistical differences 
(p<0.05) were shown between samples evaluated in all media. 
   
Figure 3-7 G3 hydrogel pH-dependent degradation at 37˚C. 
3.7 Scanning electronic microscopy (SEM) 
Scanning electron microscopy was applied to exam micro structure of drug-loaded hydrogel 
before and after dialysis.  SEM micrographs of the drug-loaded and purified G3 and G4.5 
hydrogels are presented in Figure 3-8 and Figure 3-9 respectively. The hydrogel samples 
possessed an interconnected porous structure with various pore sizes from submicrometers to a 
G3 hydrogel stability in pH 4.5
0 2 4 6
85
90
95
100
105
110
Time (day)
S
ta
b
il
it
y
 d
e
g
re
e
 (
%
)
G3 hydrogel stability in pH 5.5
0 2 4 6
85
90
95
100
105
110
Time (day)
S
ta
b
il
it
y
 d
e
g
re
e
 (
%
)
G3 hydrogel stability in pH 7.4
0 2 4 6
94
96
98
100
102
104
106
Time (day)
S
ta
b
il
it
y
 d
e
g
re
e
 (
%
)
 27 
 
few micrometers. After dialysis, the hydrogels had larger micropores than those drug-loaded 
samples. Drug particles can be clearly observed in drug-loaded hydrogels. After dialysis, no 
visible drug particles can be seen in the hydrogel due to drug release. 
  
  
Figure 3-8 SEM images of G3 hydrogels containing drugs before purification (A and B) and after purification(C 
and D). 
 
A B 
C D 
 28 
 
  
  
Figure 3-9 SEM images of G4.5 hydrogels containing drugs before purification (A and B) and after purification(C 
and D). 
3.8 Brimonidine tartrate and timolol maleate release from G3 hydrogel 
Brimonidine tartrate and timolol maleate release were measured in PBS of three pHs (4.5, 5.5 
and 7.4) at 37˚C. As shown in Figure 3-10, 64.33% of brimonidine tartrate was released in pH 
4.5 PBS, 65.35% was released in pH 5.5 PBS, 72.48% was released in pH 7.4 PBS in 15 days. 
Most of the drugs were release in the first 16 hours.  Data analysis shows that no significant 
difference in brimonidine tartrate releasing was observed between the three groups.  
As shown in Figure 3-11, 60.06% of timolol maleate was released in pH 4.5 PBS, 53.44% was 
released in pH 5.5 PBS and 74.65% was released in pH 7.4 PBS over a period of 15 days. Data 
analysis shows that timolol maleate release profile in pH 4.5 PBS and pH 5.5 PBS were not 
A B 
C D 
 29 
 
significantly different. A significantly higher drug release profile was observed in pH 7.4 PBS 
than in pH 4.5 PBS and pH 5.5 PBS. 
 
Figure 3-10 Kinetics of brimonidine tartrate release from G3 hydrogel at 37˚C. 
 
Figure 3-11 Kinetics of timolol maleate release from G3 hydrogel at 37˚C. 
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3.9 G3 hydrogel WST-1 assay 
The cytotoxicity was evaluated using human corneal epithelial cells (HCECs). Untreated 
HCECs were used as a positive control. As seen in Figure 3-12, there was no significant 
difference between the sample groups and control group in terms of viability. G3 hydrogel 
degradation solution did not show cytotoxicity effect on HCECs.  This non-toxicity effect may 
be the result of slow degradation of the hydrogel in aqueous solutions.  
 
Figure 3-12 Cytotoxicity of G3 hydrogel degradation solution on HCECs. 
3.10 G3 hydrogel ELISA 
An ELISA kit was used to measure IL-1α in culture supernatants, an indicator of inflammation. 
As shown in Figure 3-13 and Figure 3-14, there was no significant difference in IL-1α release 
level between control groups and sample groups treated with G3 hydrogel degradation solution. 
The ELISA result indicated that G3 hydrogel did not induce inflammation in HCECs. 
C
on
tr
ol
S
am
pl
e
0
50
100
150
C
e
ll
 v
ia
b
il
it
y
 (
%
)
 31 
 
 
Figure 3-13 Comparison of IL-1α release from HCECs between control group and sample group treated with G3 
hydrogel degradation solution.  
 
 
Figure 3-14 Comparison of IL-1α release from HCECs between control group and each sample group treated with 
G3 hydrogel degradation solution. 
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CHARPTER 4  SUMMARY AND FUTURE WORK 
A novel clickable hydrogel utilizing G3 or 4.5 PAMAM dendrimer was synthesized and 
characterized for anti-glaucoma drug delivery. We demonstrated that the G3 hydrogel had no 
significant degradation and showed a prolonged drug release profile for anti-glaucoma drugs: 
brimonidine tartrate and timolol maleate. We demonstrated G3 hydrogel had good swelling 
property. Both WST-1 assay and ELISA showed that hydrogel did not cause toxic effect on 
human corneal epithelial cells in terms of viability and IL-1α release. 
In this formulation, copper ions may cause toxicity to cells by destructing cells’ metabolic 
pathway and preventing proliferation. To address it, we suggest two solutions. From drug 
loading perspective, the formulation could be constructed by soaking purified hydrogel in high-
concentration drug solution, in other words, by loading drugs after copper ions’ removal. 
Concerning drugs’ solubility, this method may be inefficient in loading lipophilic drugs. Another 
solution is from synthetic perspective, which is more fundamental by using copper-free click 
chemistry to synthesize hydrogel. In this way, the use of EDTA for removal of copper ions can 
be avoided. It also helps maintain hydrogel’s original micro morphology and mechanical 
property.  
In this work, in vitro drug release profiles were obtained. Further studies will examine in vivo 
pharmacokinetics and pharmacodynamics of the delivered drug and conduct safety assessment. 
Clickable hydrogel can also be explored to deliver a broad spectrum of therapeutics, such as 
small molecular weight drugs, nucleic acids, peptides and proteins to treat various diseases.  
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APPENDIX 
1. Swelling property 
Degree of swelling (%) 
time(min) Sample #1 Sample #2 sample#3 mean SD 
0 0% 0% 0% 0% 0 
5 102% 113% 114% 110% 0.06248355 
10 168% 156% 178% 167% 0.107891802 
20 259% 216% 242% 239% 0.216185365 
30 288% 250% 281% 273% 0.200640784 
40 298% 281% 278% 286% 0.105631369 
50 310% 288% 297% 298% 0.111576096 
60 312% 303% 297% 304% 0.075420778 
70 312% 303% 297% 304% 0.075420778 
100 320% 309% 308% 312% 0.061754183 
130 327% 309% 311% 316% 0.096153179 
160 332% 313% 308% 318% 0.124674594 
220 334% 319% 317% 323% 0.095474834 
280 344% 313% 319% 325% 0.164951103 
340 349% 322% 325% 332% 0.147149725 
460 351% 331% 333% 339% 0.109775308 
580 356% 334% 339% 343% 0.114628621 
1540 361% 341% 336% 346% 0.13246168 
1640 361% 344% 342% 349% 0.105979337 
1740 361% 344% 342% 349% 0.105979337 
1840 361% 347% 339% 349% 0.111835326 
2. Degradation property 
time 
(day) 
Remaining weight/initial weight in 
pH=4.5 
Remaining weight/initial weight 
pH=5.5 
Remaining weight/initial weight in 
pH=7.4 
#1 #2 #3 #1 #2 #3 #1 #2 #3 
0 1 1 1 1 1 1 1 1 1 
1 1 1 1 1 1 1 1 1 1 
2 1 1 1 1 1 1 1 1 1 
3 1 1 1 1 1 1 1 1 1 
4 1 0.909091 1 1 1 1 1 1 1 
5 1 0.909091 1 1 1 0.923077 1 1 1 
Time 
(day) 
Sustainable degree in pH=4.5 Sustainable degree in pH=5.5 Sustainable degree in pH=7.4 
mean sd n mean sd n mean sd n 
0 1 0 3 1 0 3 1 0 3 
1 1 0 3 1 0 3 1 0 3 
2 1 0 3 1 0 3 1 0 3 
3 1 0 3 1 0 3 1 0 3 
4 0.969697 0.052486 3 1 0 3 1 0 3 
5 0.969697 0.052486 3 0.974359 0.044412 3 1 0 3 
 
Parameter 
Table Analyzed Data 1 
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One-way analysis of variance 
P value 0.3001 
P value summary ns 
Are means signif. different? (P < 0.05) No 
Number of groups 3 
F 1.306 
R squared 0.1483 
 
Bartlett's test for equal variances 
Bartlett's statistic (corrected) 
P value 
P value summary ns 
Do the variances differ signif. (P < 0.05) No 
 
ANOVA Table SS df MS 
Treatment (between columns)0.0003085 2 0.0001543 
Residual (within columns) 0.001772 15 0.0001181 
Total 0.002081 17 
 
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
PH=4.5 vs PH=5.5 -0.005827 1.313 No ns -0.02213 to 0.01048 
PH=4.5 vs PH=7.4 -0.01010 2.276 No ns -0.02640 to 0.006202 
PH=5.5 vs PH=7.4 -0.004274 0.9630 No ns -0.02058 to 0.01203 
3. Timolol maleate release 
time hour 
pH=4.5 pH=5.5 pH=7.4 
#1 #2 #3 #1 #2 #3 #1 #2 #3 
1 0.4072 0.4324 0.4311 0.3913 0.4368 0.4311 0.4689 0.4819 0.4554 
2 0.4328 0.4404 0.4324 0.3945 0.4485 0.443 0.4961 0.5254 0.472 
4 0.4558 0.4664 0.4593 0.4241 0.4582 0.4574 0.5246 0.563 0.5114 
16 0.4727 0.4927 0.5089 0.4521 0.4645 0.477 0.5836 0.6043 0.5553 
40 0.5087 0.5255 0.5278 0.4675 0.4656 0.4854 0.5952 0.6085 0.5591 
64 0.5327 0.5531 0.5556 0.4838 0.4791 0.493 0.6088 0.6322 0.572 
88 0.5674 0.5619 0.5654 0.4934 0.4962 0.4937 0.6374 0.644 0.5875 
112 0.5907 0.5671 0.5807 0.499 0.4984 0.4943 0.6531 0.6769 0.6059 
136 0.5945 0.5683 0.5832 0.528 0.5053 0.503 0.6817 0.7047 0.6148 
160 0.6065 0.5714 0.5842 0.5283 0.5055 0.5077 0.7065 0.7131 0.6478 
184 0.617 0.5761 0.5896 0.5461 0.5143 0.5143 0.7448 0.7387 0.666 
352 0.6309 0.5777 0.5933 0.5549 0.5152 0.5332 0.8053 0.7542 0.68 
time hour 
pH=4.5 pH=5.5 pH=7.4 
mean SD N mean SD N mean SD N 
1 0.423567 0.014189 3 0.419733 0.024788 3 0.468733 0.013251 3 
2 0.4352 0.004508 3 0.428667 0.029717 3 0.497833 0.026742 3 
4 0.4605 0.005401 3 0.446567 0.019461 3 0.533 0.026806 3 
16 0.491433 0.018133 3 0.464533 0.01245 3 0.581067 0.024598 3 
40 0.520667 0.010427 3 0.472833 0.010924 3 0.5876 0.025562 3 
64 0.547133 0.012562 3 0.4853 0.00707 3 0.604333 0.030348 3 
88 0.5649 0.002784 3 0.494433 0.001537 3 0.622967 0.030892 3 
112 0.5795 0.011846 3 0.497233 0.002558 3 0.6453 0.036137 3 
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136 0.582 0.013141 3 0.5121 0.013818 3 0.667067 0.046702 3 
160 0.587367 0.017763 3 0.513833 0.012577 3 0.689133 0.035948 3 
184 0.594233 0.02084 3 0.5249 0.01836 3 0.7165 0.043841 3 
352 0.600633 0.027348 3 0.534433 0.019879 3 0.7465 0.063004 3 
Parameter 
Table Analyzed Data 1 
 
One-way analysis of variance 
P value 0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
Number of groups 3 
F 12.13 
R squared 0.4237 
 
Bartlett's test for equal variances 
Bartlett's statistic (corrected) 6.613 
P value 0.0367 
P value summary * 
Do the variances differ signif. (P < 0.05) Yes 
 
ANOVA Table SS df MS 
Treatment (between columns)0.1041 2 0.05206 
Residual (within columns) 0.1416 33 0.004291 
Total 0.2457 35 
 
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
PBS PH=4.5 vs PBS PH=5.5 0.04938 2.611 No ns -0.01629 to 0.1151 
PBS PH=4.5 vs PBS PH=7.4 -0.08107 4.287 Yes * -0.1467 to -0.01540 
PBS PH=5.5 vs PBS PH=7.4 -0.1305 6.899 Yes *** -0.1961 to -0.06478 
 
4. Brimonidine tartrate release 
 
time hour 
pH=4.5 pH=5.5 pH=7.4 
#1 #2 #3 #1 #2 #3 #1 #2 #3 
1 0.4896 0.3708 0.3607 0.4335 0.4368 0.4441 0.4386 0.3911 0.3778 
2 0.5251 0.419 0.3993 0.5173 0.5124 0.5236 0.5587 0.4708 0.4497 
4 0.5998 0.5529 0.5683 0.5709 0.5522 0.5901 0.6148 0.5533 0.5192 
16 0.689 0.5614 0.5903 0.5898 0.5798 0.6336 0.648 0.5903 0.611 
40 0.69 0.5617 0.5924 0.5935 0.5821 0.6375 0.6604 0.6094 0.6291 
64 0.6914 0.5622 0.5934 0.6034 0.5832 0.6527 0.6663 0.6284 0.6406 
88 0.6916 0.5665 0.5947 0.6079 0.5851 0.6611 0.6966 0.644 0.6606 
112 0.6926 0.5666 0.5976 0.6125 0.5969 0.6664 0.7048 0.653 0.6705 
136 0.6947 0.5743 0.5995 0.6242 0.5965 0.6678 0.7324 0.6629 0.6844 
160 0.7 0.5746 0.6101 0.6281 0.6064 0.6691 0.7352 0.6643 0.6917 
184 0.7121 0.5801 0.6117 0.6329 0.617 0.6736 0.7419 0.671 0.7119 
352 0.7284 0.5803 0.6211 0.6501 0.6235 0.6868 0.7627 0.6842 0.7275 
Time (hour) 
pH=4.5 pH=5.5 pH=7.4 
Mean SD N Mean SD N Mean SD N 
1 0.407033 0.071683 3 0.438133 0.005424 3 0.4025 0.031963 3 
2 0.4478 0.067665 3 0.517767 0.005615 3 0.493067 0.057811 3 
4 0.573667 0.023906 3 0.571067 0.018951 3 0.562433 0.04845 3 
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16 0.613567 0.066906 3 0.601067 0.028615 3 0.616433 0.029231 3 
40 0.6147 0.066994 3 0.604367 0.029255 3 0.632967 0.025719 3 
64 0.615667 0.067417 3 0.6131 0.035751 3 0.6451 0.019347 3 
88 0.6176 0.065619 3 0.618033 0.039 3 0.667067 0.02689 3 
112 0.618933 0.065653 3 0.625267 0.036466 3 0.6761 0.02635 3 
136 0.622833 0.063501 3 0.6295 0.035944 3 0.693233 0.035582 3 
160 0.628233 0.064637 3 0.634533 0.031841 3 0.697067 0.035753 3 
184 0.634633 0.068924 3 0.641167 0.029191 3 0.708267 0.035589 3 
352 0.643267 0.076498 3 0.653467 0.031784 3 0.7248 0.03932 3 
Parameter 
Table Analyzed Data 1 
 
One-way analysis of variance 
P value 0.4411 
P value summary ns 
Are means signif. different? (P < 0.05) No 
Number of groups 3 
F 0.8390 
R squared 0.04839 
 
Bartlett's test for equal variances 
Bartlett's statistic (corrected) 2.146 
P value 0.3419 
P value summary ns 
Do the variances differ signif. (P < 0.05) No 
 
ANOVA Table SS df MS 
Treatment (between columns)0.01060 2 0.005299 
Residual (within columns) 0.2084 33 0.006316 
Total 0.2190 35 
 
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
PBS PH=4.5 vs PBS PH=5.5 -0.009128 0.3979 No ns -0.08880 to 0.07054 
PBS PH=4.5 vs PBS PH=7.4 -0.04009 1.748 No ns -0.1198 to 0.03958 
PBS PH=5.5 vs PBS PH=7.4 -0.03096 1.350 No ns -0.1106 to 0.04871 
 
5. WST-1 
Analysis method: t test 
Table Analyzed Data 1 
Column A Control 
vs vs 
Column B Sample 
    
Unpaired t test   
P value 0.6178 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.5190 df=8 
    
How big is the difference?   
Mean ± SEM of column A 100.0 ± 3.644 N=5 
Mean ± SEM of column B 94.85 ± 9.230 N=5 
Difference between means 5.150 ± 9.923 
95% confidence interval -17.73 to 28.03 
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R squared 0.03257 
    
F test to compare variances   
F,DFn, Dfd 6.415, 4, 4 
P value 0.0993 
P value summary ns 
Are variances significantly different? No 
 
6. ELISA result (two groups) 
 
 
Table Analyzed Data 1 
Column A NA 
vs vs 
Column B Sample 
  
Unpaired t test  
  P value 0.7378 
  P value summary ns 
  Are means signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  t, df t=0.3406 df=16 
  
How big is the difference?  
  Mean ± SEM of column A 398.3 ± 6.485 N=5 
  Mean ± SEM of column B 393.6 ± 8.071 N=13 
  Difference between means 4.700 ± 13.80 
  95% confidence interval -24.56 to 33.96 
  R squared 0.007198 
  
F test to compare variances  
  F,DFn, Dfd 4.028, 12, 4 
  P value 0.1896 
  P value summary ns 
  Are variances significantly different? No 
 
 
7. ELISA (four groups)     
      
One-way analysis of variance      
  P value 0.0282     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 4     
  F 4.077     
  R squared 0.4663     
      
ANOVA Table SS df MS   
  Treatment (between columns) 5069 3 1690   
  Residual (within columns) 5801 14 414.4   
  Total 10870 17    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
  NA vs Sample 1 22.50 2.472 No ns -14.93 to 59.93 
  NA vs Sample 2 11.30 1.170 No ns -28.40 to 51.00 
  NA vs Sample 3 -23.70 2.454 No ns -63.40 to 16.00 
 
